Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-26
DOI
10.1007/s00262-021-02906-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Resistance to Checkpoint Inhibition in Cancer Immunotherapy
- (2020) Luisa Barrueto et al. Translational Oncology
- The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma
- (2019) Heike Loeser et al. OncoImmunology
- Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma
- (2019) Michael Lattanzi et al. Current Oncology Reports
- European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update
- (2019) Marko Babjuk et al. EUROPEAN UROLOGY
- VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
- (2019) Liju Zong et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma
- (2018) Ming Zhang et al. BMC CANCER
- VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival
- (2018) Lawrence F. Kuklinski et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers
- (2018) Gladell P. Paner et al. EUROPEAN UROLOGY
- Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma
- (2018) Arlene O. Siefker-Radtke et al. JOURNAL OF UROLOGY
- Role of immunotherapy in bacillus Calmette–Guérin-unresponsive non–muscle invasive bladder cancer
- (2018) Neelam Mukherjee et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Expression of V‑domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer
- (2018) Hong Liao et al. Oncology Letters
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors
- (2018) Shan Xie et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Urothelial cancer: a narrative review of the role of novel immuno-therapeutic agents with particular reference to the management of non- muscle invasive disease
- (2018) E Doyle et al. BJU INTERNATIONAL
- VISTA expressed in tumour cells regulates T cell function
- (2018) Kumuluzi Mulati et al. BRITISH JOURNAL OF CANCER
- Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review
- (2017) Viktor Soukup et al. EUROPEAN UROLOGY
- Immunoregulatory functions of VISTA
- (2017) Elizabeth C. Nowak et al. IMMUNOLOGICAL REVIEWS
- Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy
- (2017) David D. Chism Journal of the National Comprehensive Cancer Network
- Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Philippe E. Spiess et al. Journal of the National Comprehensive Cancer Network
- Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer
- (2017) Karthik V. Giridhar et al. MAYO CLINIC PROCEEDINGS
- Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
- (2017) Hojabr Kakavand et al. MODERN PATHOLOGY
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
- (2017) Ashish M. Kamat et al. Journal for ImmunoTherapy of Cancer
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
- (2016) Sam S. Chang et al. JOURNAL OF UROLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- PD-L1 expression as a potential predictive biomarker
- (2015) Alberto Fusi et al. LANCET ONCOLOGY
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
- (2015) Jun Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- VISTA Is an Immune Checkpoint Molecule for Human T Cells
- (2014) J. L. Lines et al. CANCER RESEARCH
- VISTA Regulates the Development of Protective Antitumor Immunity
- (2014) I. Le Mercier et al. CANCER RESEARCH
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started